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Abstract
Background: We report an economic analysis of Human Immunodeficiency Virus (HIV) care and treatment in Indonesia
to assess the options and limitations of costs reduction, improving access, and scaling up services.
Methods: We calculated the cost of providing HIV care and treatment in a main referral hospital in West Java, Indonesia
from 2008 to 2010, differentiated by initiation of treatment at different CD4 cell count levels (0–50, 50–100, 100–150,
150–200, and >200 cells/mm3); time of treatment; HIV care and opportunistic infections cost components; and the costs
of patients for seeking and undergoing care.
Discussion: Before antiretroviral treatment (ART) initiation, costs were dominated by laboratory tests (>65 %), and
after initiation, by antiretroviral drugs (≥60 %). Average treatment costs per patient decreased with time on
treatment (e.g. from US$580 per patient in the first 6 month to US$473 per patient in months 19–24 for those
with CD4 cell counts under 50 cells/mm3). Higher CD4 cell counts at initiation resulted in lower laboratory and
opportunistic infection treatment costs. Transportation cost dominated the costs of patients for seeking and
undergoing care (>40 %).
Conclusions: Costs of providing ART are highest during the early phase of treatment. Costs reductions can potentially
be realized by early treatment initiation and applying alternative laboratory tests with caution. Scaling up ART at the
community level in certain high prevalence settings may improve early uptake, adherence, and reduce transportation
costs.
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Background
The face of the HIV/AIDS epidemic in Indonesia is
changing. While the epidemic started among injecting
drug users, now it is shifting towards the general popula-
tion. The percentage of HIV transmission through
injecting drug use decreased from 13 % in 2010 to 7 %
in 2014, and heterosexual transmission increased from
31 to 52% during the same period [1].
Indonesia’s national response to the epidemic focuses
on a wide range of programs, including continuing sup-
port for care and treatment programs [2]. The need for
antiretroviral therapy (ART) is expected to increase from
approximately 30,000 patients in 2008 to almost 87,000
patients in 2014 [3]. However, only 24 % of people living
with HIV (PLHIV) who are eligible for treatment in
Indonesia receive ART which indicates the need for the
government to increase ART services, and puts pressure
on the already-constrained budget for HIV/AIDS control
in Indonesia [4]. The guideline for providing ART in
Indonesia has also changed. Since 2011, the treatment
was given to patients with CD4 cell count of less than
350 cells/mm3, with the exception of pregnant women
with HIV, babies born from women with HIV, and
PLHIV with TB and Hepatitis B who are not yet on ART
(these PLHIV received ART regardless of their CD4 cell
count) [5, 6]. In 2014 this guideline was revised. While
the CD4 cell count cut- off remained the same, the
list of groups of PLHIV who are eligible for ART
regardless of their CD4 cell count were extended.
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This now includes PLHIV with Hepatitis C, children
under five with HIV, high risk groups with HIV, sero-
discordant couples, and PLHIV living in a region with
increasing HIV epidemic [7]. In this respect, the in-
formation on costs of HIV treatment becomes even
more important.
There is an urgent need to address the following
research questions. First, what are the present treatment
costs per person per year, by time of treatment and stage
of disease, and is there any potential to reduce these
costs? There is very little evidence on this question from
the Indonesian context. Yet, in recent years, much
evidence has become forward from African studies. For
example, a recent multi-country study including 161
facilities has shown that facility-level ART costs on aver-
age $208 per patient-year across Ethiopia, Malawi,
Rwanda and Zambia. Costs were higher in South Africa,
at $682 [8]. Another study, using multiple independent
mathematical models in four settings-South Africa,
Zambia, India, and Vietnam- concluded that early initi-
ation of ART (at CD4 levels ≤500 cells/μL) is more cost-
effective than late treatment [9]. Also, there is (limited)
international evidence that delivery of ART is less costly
at the community level than at the hospital level [10].
The limited Indonesian data that is available suggests
that the use of less intense diagnostic and treatment
procedures might lead to cost savings [11–13]; however,
this data has not been placed in the context of total
treatment costs.
Second, what are the costs of scaling up ART? Inter-
national evidence suggests that cost increases stemming
from increased patient numbers can partly be offset by
reduced average treatment costs as patients are treated
earlier [14]; however, there is no specific evidence for
Indonesia to support this hypothesis.
Third, what is the financial burden of patients acces-
sing care? Although international studies have shown
that the financial burden on patients may constitute a
barrier to treatment [15] and may affect adherence and
retention to treatment (unpublished data [13, 14]),
available evidence from Indonesia stems from a single
study only [16].
This paper presents an economic analysis of the
provision of ART and care for HIV/AIDS patients from
both the health care provider and patient perspectives. It
presents a cost profile differentiated by initiation of
treatment at different CD4 cell count levels; time on
treatment; cost components (e.g., drug and personnel
costs) for HIV care and opportunistic infections (OIs);
and finally patient costs of seeking and undergoing care.
We believe our approach is unique in the context of
Indonesia and Asia and can be generalized to other
settings with similar HIV/AIDS epidemics and health
system profiles.
Methods
Study setting and study population
The study was conducted in Bandung, at an HIV/AIDS
clinic in the largest public referral and teaching hospital
(Hasan Sadikin) in West Java province (43 million inhab-
itants). The clinic is visited by high risk groups and the
general population, and delivers HIV-related services
such as voluntary counseling and testing, ART, and sexu-
ally transmitted infections services. The clinic operates at
full capacity because it is among the few clinics that
deliver ART in Bandung. The clinic generates its own
revenues through government, hospital, and private fund-
ing; ART-related services are free, except hospitalization
and the registration fee.
The study included all records on inpatients and out-
patients starting ART in the clinic between 2008 and
2010. The study population was divided into five groups
by CD4 cell count: 0–50, 50–100, 100–150, 150–200,
and >200 cells/mm3. The starting point of every patient
initiating ART was uniformed as month 1, and patients
were analyzed at 6, 12, 18, and 24 months on ART. We
also observed the pre-ART period when patients
received HIV care and treatment but had not yet initi-
ated ART, which ranged from 1 week to 6 months before
treatment initiation. Based on these starting points, each
patient’s treatment pattern was tracked from available
medical and financial records and all costs were calcu-
lated. Patients were required to visit the clinic monthly
to take their antiretroviral drugs (ARVs), and undergo
CD4 cell count, viral load, and routine laboratory tests
approximately every 6 months.
Data collection and cost estimation
The cost estimation was divided into health care costs
(costs related to the consumption of resources in the
health care system) and patient costs (costs falling on
the patient for seeking and undergoing care). Health care
costs were divided into hospitalization, outpatient visits,
OI treatment, and ARVs, as well as CD4 cell count, viral
load, and routine laboratory test costs. The micro-
costing approach [17] was used to calculate the unit cost
of an outpatient visit and OI treatment. All resources
consumed, prices, and salaries related to service utilization
were listed and estimated based on clinical records,
pharmacy databases, staff interviews, government price
standards, and hospital or market prices.
Outpatient costs were calculated based on the total
recurrent and capital costs of the clinic. Recurrent
personnel costs were estimated based on actual wages or
government salary scales [18]. Other recurrent costs (e.g.,
administration goods consumed during the observation
period) were estimated using both actual and market
prices. Capital costs included trainings and workshops
attended by the clinic staff, and unit costs for organizing
Siregar et al. BMC Health Services Research  (2015) 15:440 Page 2 of 12
these activities were obtained from the actual budgetary
or governmental records. Market prices were used to esti-
mate other capital costs, including equipment, furniture,
and start-up costs (e.g., renovation costs, if applicable).
Capital costs were subsequently annualized on the basis of
the lifetime of the capital items, using a 3 % discount rate
[17]. We omitted the cost of utilities (i.e., water and elec-
tricity). This result was then multiplied by the proportion
of time allocated by the clinic to deliver ART, calculated
through a separate time motion study in which we
observed (in a week time, within the clinic) all clinical
activities and calculated the amount of time spent on
ART-related duties per week by the clinic staff. The
total outpatient visit cost was then divided by the
number of total outpatient visits to obtain the unit
cost per outpatient visit. Patients registered as out-
patient were never also registered as inpatient in the
same period. For example, a patient who is registered
as inpatient in a certain month may be registered as
outpatient in the next month, but never at the same
month. The details of the outpatient cost are pre-
sented in the Appendix: Table 6).
The OI treatment costs were calculated based on the
medical resources consumed by OI treatment (e.g., drugs
and equipment), excluding hospitalization. Medical
records and the physician’s patient database were used
to estimate resource utilization, and the official hospital
prices issued in 2011 were used to calculate the unit
costs of drugs and equipment. We obtained the unit cost
of OI treatment by dividing the total cost of OI treatment
for each CD4 cell count group by its population. We were
unable to retrieve data regarding the specific OIs that
drugs and equipment were used to treat. The average unit
cost of OI treatment is presented in Appendix: Table 7).
Because the data was limited, we did not perform micro-
costing when calculating the costs of hospitalization, ARVs,
or laboratory tests. We used the World Health Organiza-
tion’s Choosing Interventions that are Cost Effective
(WHO-CHOICE) estimates [19] to estimate the per day
inpatient hotel cost, which we then used to calculate the
total hospitalization cost. The WHO-CHOICE estimates
for inpatient cost include items such as personnel, capital,
and food costs, and exclude drugs and diagnostic test
costs. The prices of ARV drugs (except for Tenofovir)
issued by Kimia Farma (a national pharmaceutical
corporation) were used as the unit costs of ARVs,
while the price of Tenofovir was based on Bender et
al. [20]. The unit costs of laboratory tests (CD4 cell
count, viral load, and other laboratory tests) were de-
rived from the 2011 official hospital price for each
test. The summary of all unit costs used is presented
in the Appendix: Table 8).
The patient costs were estimated by conducting a survey
among 41 patients undergoing ART at the hospital. We
collected information including (but not limited to) clinic
service fee, travel costs, travelling time, the average num-
ber of daily working hours, and monthly expenditures.
Based on this information, first we calculated the amount
of productive time per patient (in minutes), basically total
time spent at work per month in minutes. Second, we cal-
culated patient productivity per minute (i.e. monthly ex-
penditure per minute as a proxy for income/productivity
per minute). Third, we estimated the total productivity
loss per patient as the amount of minutes spent to
undergo the treatment (i.e. time spent for traveling,
queueing/waiting, and treatment) times patient productiv-
ity per minute. Patients did not have to pay for ARV, ARV
monitoring, other lab tests, or OI medication/treatment.
To avoid double counting in calculating treatment costs
from the societal perspective, we exempted the clinic
service fee from this specific calculation (but it is
included in the patient cost calculation).
All costs were measured in Rupiah, and converted to
US$ using the 2010 exchange rate [21]. Both the
utilization and cost data were analyzed using Microsoft
Excel 2007. We report the costs from both health care
system and patient perspectives, and performed statistical
tests to find out the significance of any costs differences
between period and CD4 cell count level.
Secondary data related to patients (e.g. ARV and OI
drugs intake per patient) were taken from the clinic’s
patients database (in the form of an Excel file). The
database was anonymized prior to analysis (we utilize
the patients hospital ID number during analysis), and
none of the patients personal identity was published
in any part of the study. On the event of patient
costs (primary) data collection, all patients were asked
to fill in written informed consent forms prior to
participating in the survey and the survey was
anonymous (no patient names were collected). The
survey was conducted by a group of enumerators and
authors only received the results. The study was
approved by the Padjadjaran University Indonesia,
Medical Faculty ethical committee.
Results
Patient characteristics
Patient characteristics are presented in Table 1. The major-
ity of patients within the CD4 cell count of 0 – 150 cells/
mm3 group are males (151 male, 34 female), while females
dominate the >150 cells/mm3 group (11 male, 16 female).
In average, there are more males across the CD4 cell count
groups (72 %). The average age of patients across the
groups is 30 years old, and the majority are married,
employed, and have experience with injecting drug use.
The highest education level attained by patients was the
secondary level (high school).
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Resource utilization and costs of providing ART
Table 2 presents the resources used to provide ART.
Hospitalization occurred only before ART and up to
6 months after treatment was initiated; the duration
ranged from 3 to 20 days. The switch to second line
ART occurred in 5 % of patients with a CD4 cell count
of 0 − 50 cells/mm3 and 15 % of those with 50 − 100
cells/mm3. Few patients with CD4 cell counts >200
cells/mm3 were hospitalized and received OI treatment.
Details regarding unit costs per item are summarized in
the Appendix: Table 8).
Table 3 details the costs associated with providing ART.
Before ART initiation, costs were mainly dominated by la-
boratory tests (including the CD4, viral load, and routine
laboratory tests). After the initiation of ART, costs were
dominated by ARV, regardless of patients’ CD4 levels.
Both total costs and per patient average costs decreased
over time after ART initiation. The one anomaly was
the OI drugs/treatment cost for patients with a CD4
level of 50 − 100 cells/mm3, which increased from
US$725 in 1–6 months to US$2099 in 7–12 months. A
relatively high CD4 cell count at treatment initiation
relates to relatively low costs of ARVs, laboratory tests,
and OI drugs/treatment. Figure 1 shows the average
costs per patient for different CD4 cell count levels and
over time. The highest average costs for 24 months of
ART per patient were for patients with a CD4 cell
count <50 cells/mm3. The distribution of cost is provided
in the Appendix: Figure 2). The average costs difference
between patients undergoing the first 6 months of treat-
ment and the 24 months of treatment is statistically
significant within the group of patients with CD4 cell
count < 50 cells/mm3, 50 – 100 cells/mm3, and those
with >200 cells/mm3. The average 2 year treatment costs
difference between the patients with CD4 cell count < 50
cells/mm3 and the groups with higher CD4 cell count is
also statistically significant, except with patients with CD4
cell count between 100 – 150 cells/mm3. The statistical
significance test is summarized in Appendix: Table 9.
Patient costs per visit
Table 4 presents patient costs. The average patient costs
per visit are US$10 and US$11, for patients with CD4 cell
counts below and above 200 cells/mm3, respectively.
Transportation cost and the clinic fee dominated the
costs, while productivity loss accounted for less than 25 %
of the total cost per visit. Per visit, almost all patients
spent US$2 for the registration fee and US$5 −US$6 for
transportation. The mean time to reach the clinic was
approximately 1 h (most patients lived < 20 km away) and
the average time spent in the clinic was approximately 100
min. There were no major differences in patient costs
between patients with CD4 cell counts less than or greater
than 200 cells/mm3 (we did not perform significance test
for this due to our small sample size). Most patients in
our survey travelled using either public transport (54 %)
or motorcycle (42 %).
Discussion
To our knowledge, this study is the first in Indonesia
and among the few in Asia [22, 23] to estimate the cost
of providing ART. The overall cost profile shows that
the total costs and average costs per patient are
Table 1 Characteristics of patients on ART
CD4 cell count at time of starting ART
0–50 50–100 100–150 150–200 >200 Overall
No. of observation at the start of ART 96 33 22 17 10 178
CD4 level at the start of ART , meana 19 (16 – 22) 71 (66 – 76) 124 (118 – 130) 177 (170–184) 275 (252 – 298) 39 (13–110)b
Sex (male) 80 % 82 % 59 % 41 % 40 % 72 %
Age, meana 30 (29 - 31) 30 (28–32) 29 (28–30) 27 (26–28) 27 (25 – 29) 30 (29–31)
History of injecting drug use 69 % 70 % 55 % 41 % 70 % 65 %
Marital status Married 52 % 58 % 45 % 35 % 60 % 51 %
Not married 36 % 24 % 41 % 29 % 10 % 33 %
Widowed/ divorced 10 % 15 % 14 % 29 % 30 % 15 %
Occupation status Employed 67 % 82 % 86 % 82 % 80 % 74 %
Student 2 % - - 6 % - 2 %
Unemployed 30 % 15 % 14 % 12 % 20 % 23 %
Highest education Primary 3 % - - - - 2 %
Secondary 58% 51 % 59 % 77 % 80 % 60 %
Tertiary 36 % 48 % 41 % 24 % 20 % 37 %
a95 % CI, bMedian (IQR)
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Table 2 Resource utilization of patients on ART by CD4 cell count at the start of ART, per specified period
CD4 cell
count
Item Period Average
1–24 monthsBefore ART 1–6 months 7–12 months 13–18 months 19–24 months
0–50 Number of patients 96 96 95 84 61
% hospitalizeda 14 % 22 % - - -
Average days of hospitalizationb 6 (4–8) 15 (10–20) - - - 0.2c
Number of outpatient visit 95 47 75 63 41 3c
% of patients treated for OIa 2 % 63 % 27 % 18 % 8 % 29 %
% switched to 2nd line ARVa - - 1 % 2 % 3 % 2 %
Number of CD4 tests 95 47 75 63 41 3c
Number of viral load tests - 6 16 9 4 0.4c
Number of routine lab tests 87 45 74 62 40 3c
50–100 Number of patients 33 33 33 32 25
% hospitalizeda 3 % 12 % - - -
Average days of hospitalizationb 3 6 (5–7) - - - 0.2c
Number of outpatient visit 36 13 29 20 10 2c
% of patients treated for OIa 3 % 36 % 21 % 13 % 4 % 19 %
% switched to 2nd line ARVa - 3 % 3 % 6 % 12 % 7 %
Number of CD4 tests 36 13 29 20 10 2c
Number of viral load tests - 5 6 4 - 0.5c
Number of routine lab tests 30 14 28 20 9 2c
100–150 Number of patients 22 22 22 18 13
% hospitalizeda - 14 % - - -
Average days of hospitalizationb - 7 - - - 0.3c
Number of outpatient visit 29 8 18 13 7 2c
% of patients treated for OIa - 45 % 18 % 11 % 15 % 22 %
% switched to 2nd line ARVa - - - - -
Number of CD4 tests 29 8 18 13 7 2c
Number of viral load tests 1 1 4 3 - 0.4c
Number of routine lab tests 21 8 17 13 7 2c
150–200 Number of patients 16 16 13 13 11
% hospitalizeda 12 % 6 % - - -
Average days of hospitalizationb 5 3 - - - 0.2c
Number of outpatient visit 26 9 9 11 7 3c
% of patients treated for OIa - 47 % 14 % 21 % - 27 %
% switched to 2nd line ARVa - - - - -
Number of CD4 tests 26 9 9 11 7 3c
Number of viral load tests 1 4 4 1 - 0.6c
Number of routine lab tests 16 8 9 11 7 3c
>200 Number of patients 10 10 10 7 4
% hospitalizeda - - - - -
Average days of hospitalizationb - - - - -
Number of outpatient visit 17 5 6 4 4 3c
% of patients treated for OIa - 10 % - - - 10 %
% switched to 2nd line ARVa - - - - -
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reduced when patients’ CD4 levels are higher at the
time of clinic enrollment and ART initiation. In most
instances, hospitalization, OI treatment, and ART aver-
age costs per patient decrease with longer use of ART.
During the early phase of the treatment, the highest
costs are the costs of hospitalization, OI treatment, and
ART initiation; these costs decrease over time as a re-
sult of patients’ improved health. This trend is compar-
able with the results of a study conducted in Southern
Africa [24].
These findings lead to several observations in response
to the research questions. Regarding the cost of treat-
ment and potential cost reduction, the study confirms
the hypothesis that the following measures have poten-
tial to reduce cost in ART delivery:
1) Early ART initiation. Most cost items are lower
when patients’ CD4 cell counts are higher at ART
initiation and especially the total cost share of
hospitalization and OI treatment was reduced. CD4
cell counts can predict the likelihood of OIs;
patients with CD4 cell counts >200 cells/mm3appear
to be at lower risk for the majority of OIs, compared
with patients with <200 cells/mm3 [25–28] and this
explains our study results. Early treatment is also
cost effective in resource-limited settings as well as
on the global epidemic setting [9, 29, 30]. Additionally,
the NIAID START Trial shows that early ART
protects the health of PLHIV [31]. WHO is now
preparing for a new ARV provision guideline in which
it may recommend an even earlier ART initiation
compared to its 2013 guideline [32]. Thus, our
recommendation is strengthened by the WHO
discussion and it warrants further attention. The costs
implication of prolonged treatment, however, should
be further studied to determine whether the costs re-
duction and long term costs saving resulting from early
treatment offset the costs of prolonged treatment.
2) Alternative diagnostics. Before ART initiation, costs
are dominated by laboratory tests (CD4, viral load,
and routine laboratory tests) followed by outpatient
visits and hospitalization. After ART initiation, costs
were dominated by ARV drugs followed by
laboratory tests. Although costs reductions in
hospitalization and ARV use might be difficult to
realize, reductions are possible for laboratory test
costs, as is found in the DART trial in four African
countries [33], which showed that ART can be
delivered safely without routine laboratory
monitoring for toxicity. A study within the same
hospital clinic with our study demonstrated that the
total lymphocyte count (TLC) is a good alternative
for CD4 cell count as it is much cheaper and easier
to implement in rural settings. Combining TLC test
results with an algorithm of simple patient
characteristics could save US$14 per patient
compared with the current scenario [11]. Also, De
Jong et al.[12] in Indonesia (study conducted at the
same clinic as our study) and Kumarasamy et al.
[34] in India found that TLC may reduce the need
for routine CD4 measurements during ART
(excepting the first year of treatment). In more
recent studies, however, it is found that TLC may
not be a reliable predictor for CD4 cell count in
HIV-infected individuals in certain settings [35, 36],
while it is reliable in others [37–41]. Therefore,
caution is needed in applying TLC test as a
replacement for CD4 test as it seems like the success
of its application is varied, depending much on the
specific settings and population in which it is applied.
In Indonesia, another method to reduce laboratory
costs is proposed by Indrati et al. [13], who found that
a dual-test or single rapid-test algorithm (instead of a
serial three-test algorithm) may be just as accurate
and more cost-effective, although the single rapid-test
should be interpreted carefully. Although these alter-
native laboratory testing methods may lead to costs
reductions, more research is needed to determine the
potential cost savings.
Regarding our second research question about scaling
up ART, the study indicates that although increased
ART coverage may cause a large increase in health ex-
penditure in the short run [23, 42], it could potentially
save costs in the long run. By reaching more people in
need of ART, assuming that these are detected at earlier
stages, costs related to opportunistic infections and
hospitalization may be avoided as has been shown in our
study. Importantly, providing ART can also act as HIV/
AIDS prevention [43, 44] because ART treatment re-
duces transmission rates. Universal voluntary HIV test-
ing and early ART could therefore have a major effect
on the HIV/AIDS epidemic and could be cost saving
[29, 45]. The costs of treatment of new HIV infections
Table 2 Resource utilization of patients on ART by CD4 cell count at the start of ART, per specified period (Continued)
Number of CD4 tests 17 5 6 4 4 3c
Number of viral load tests - - - - -
Number of routine lab tests 9 5 6 4 4 3c
afor the whole sample within the indicated period,b 95 CI%, cper patient
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Table 3 Health care costs of patients on ART by CD4 cell count at the start of ART, per specified period (US$a)
CD4 cell
count
Item Period Average
1–24 months
per patient
Before ART 1–6 months 7–12 months 13–18 months 19–24 months
0–50 Number of patients 96 96 95 84 61
Hospitalization 1483 (10 %) 6161 (9 %) - - - 64
Outpatient visits 1110 (8 %) 6707 (10 %) 6462 (12 %) 5247 (11 %) 3517 (11 %) 258
OI treatment 86 (1 %) 10867 (16 %) 2163 (4 %) 564 (1 %) 1538 (5 %) 168
ARV drugs - 40012 (60 %) 41281 (78 %) 37724 (81 %) 26915 (81 %) 1742
CD4 test 1254 (9 %) 620 (1 %) 990 (2 %) 832 (2 %) 541 (2 %) 36
Viral load test - 396 (1 %) 1056 (2 %) 594 (1 %) 264 (1 %) 27
Routine lab test 10452 (73 %) 1488 (2 %) 1289 (2 %) 1548 (3 %) 363 (1 %) 53
Total costs 14377 (100 %) 66205 (100 %) 53196 (100 %)c 46472 (100 %c 33115 (100 %)c 2346
Average costs per patientb 150 (139 – 160) 690 (593–787) 560 (521–599) 553 (515–592) 543 (480–606)
50–100 Number of patients 33 33 33 32 25
Hospitalization 57 (1 %) 418 (2 %) - - - 13
Outpatient visits 421 (9 %) 2337 (12 %) 2232 (11 %) 1951 (11 %) 1110 (11 %) 244
OI treatment 12 (0.3 %) 725 (4 %) 2099 (10 %) 13 (0.1 %) 9 (0.1 %) 86
ARV drugs - 14694 (77 %) 15360 (73 %) 14763 (83 %) 9058 (87 %) 1734
CD4 test 475 (10 %) 172 (1 %) 383 (2 %) 264 (1 %) 132 (1 %) 30
Viral load test - 330 (2 %) 396 (2 %) 264 (1 %) - 30
Routine lab test 3608 (79 %) 478 (2 %) 494 (2 %) 508 (3 %) 104 (1 %) 49
Total costs 4570 (100 %) 19138 (100 %) 20947 (100 %) 17749 (100 %) 10405 (100 %)c 2186
Average costs per patientb 138 (126–151) 580 (567–593) 635 (622–648) 555 (542–568) 473 (460–486)
100–150 Number of patients 22 22 22 18 13
Hospitalization - 418 (4 %) - - - 19
Outpatient visits 339 (10 %) 1566 (14 %) 1391 (13 %) 1157 (13 %) 771 (14 %) 258
OI treatment - 815 (7 %) 77 (0.7 %) 29 (0.3 %) 2 (0.04 %) 42
ARV drugs - 8147 (72 %) 8587 (79 %) 6858 (79 %) 4661 (83 %) 1500
CD4 test 383 (11 %) 106 (1 %) 238 (2 %) 172 (2 %) 92 (2 %) 32
Viral load test 66 (2 %) 66 (1 %) 264 (2 %) 198 (2 %) - 26
Routine lab test 2547 (76 %) 222 (2 %) 293 (3 %) 317 (4 %) 63 (1 %) 46
Total costs 3333 (100 %) 11329 (100 %) 10839 (100 %) 8722 (100 %) 5585 (100 %) 1922
Average costs per patientb 159 (144–173) 515 (500–529) 493 (478–507) 485 (470–499) 430 (415–444)
150–200 Number of patients 17 17 14 14 11
Hospitalization 190 (7 %) 57 (1 %) - - - 3
Outpatient visits 304 (11 %) 1133 (14 %) 982 (15 %) 935 (14 %) 654 (14 %) 263
OI treatment - 66 (1 %) 3 (0.05 %) 5 (0.1 %) - 4
ARV drugs - 6188 (77 %) 4865 (76 %) 5162 (77 %) 3717 (82 %) 1418
CD4 test 343 (12 %) 119 (1 %) 119 (2 %) 145 (2 %) 92 (2 %) 34
Viral load test 66 (2 %) 264 (3 %) 264 (4 %) 66 (1 %) - 39
Routine lab test 1969 (69 %) 200 (2 %) 195 (3 %) 362 (5 %) 63 (1 %) 57
Total costs 2870 (100 %) 8020 (100 %) 6421 (100 %) 6670 (100 %) 4522 (100 %) 1818
Average costs per patientb 169 (136–201) 472 (445–499) 459 (432–485) 476 (450–503) 411 (384–438)
>200 Number of patients 10 10 10 7 4
Hospitalization - - - - -
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will be averted and may potentially free resources to pre-
vent even more infections [14]. Considering these find-
ings, we suggest further study regarding advantages (e.g.,
health benefits of early treatment) and disadvantages
(e.g., budget impact) of scaling up ART in Indonesia
from both the short run and long run perspectives.
In terms of the location for scaling up ART, we cannot
draw strong conclusions on the basis of the costing analysis
in the hospital only. Yet, there seem to be advantages in
scaling up ART at the community level as this may poten-
tially increase early detection and reduce the burden in hos-
pital clinics [46]. Also, the shorter waiting and travel time
to the clinic may lead to lower patient’s costs and better up-
take and adherence of ART [46–49]. In this scenario, the
hospital and community health centres will have different
roles (Table 5). The hospital will be a referral centre for
complicated AIDS cases and treatment of OIs just as
current practice [46, 50]. Because patients become relatively
stable over time (indicated by decrease in hospitalization
and OI treatment over time) they could continue ART at
community clinics, reducing the hospital burden. Patients
that initiate ART at >200 cell/mm3 could also obtain ART
at the community health care center, as our analysis sug-
gests that hospitalization and OIs are rare in this popula-
tion. In addition, patients mostly utilize first line ARV, and
no patients with CD4 cell counts >100 cells/mm3 switch to
second line ARV (Table 2), indicating a low rate of treat-
ment failure within this group [51]. As such, the ARV dis-
tribution (in terms of medicine type) in community/
primary health care centres for patients with CD4 cell
counts >100 cells/mm3 might not be too complex, as most
patients are likely to require only first line ARV. Currently,
there are only two primary health care centers in Bandung
that provide ART, which presents considerable potential to
increase the service to other community clinics.
However, providing ART at all community health clinics
in Indonesia at this stage seems inefficient due to the low
HIV prevalence in the general population which will result
in a low patient load per clinic for which all community
staff will require training [52]. Therefore, providing HIV
Fig. 1 Average service costs per patient per specified period, health care system perspective (US$). This figure presents the average service costs
per patient taking ART. The average costs are separated into specific periods, namely before ART, 1–6 months, 7–12 months, 13–18 months, and
19–24 months within ART. These costs are further separated into CD4 cell count group, namely 0–50, 50–100, 100–150, 150 - 200, and >200 cells/
mm3. The figure shows how the average costs per patient in different CD4 cell count groups relatively decrease after the start of ART
Table 3 Health care costs of patients on ART by CD4 cell count at the start of ART, per specified period (US$a) (Continued)
Outpatient visits 199 (13 %) 701 (15 %) 608 (13 %) 363 (12 %) 257 (20 %) 247
OI treatment - 1 (0.02 %) - - - 0.1
ARV drugs - 3637 (79 %) 3797 (83 %) 2715 (84 %) 938 (73 %) 1366
CD4 test 224 (15 %) 66 (1 %) 79 (2 %) 53 (2 %) 53 (4 %) 35
Viral load test - - - - -
Routine lab test 1119 (73 %) 223 (5 %) 92 (2 %) 68 (2 %) 35 (3 %) 50
Total costs 1541 (100 %) 4623 (100 %) 4572 (100 %) 3218 (100 %) 1281 (100 %)c 1699
Average costs per patientb 154 (114–195) 462 (437–487) 457 (432–482) 460 (435–485) 320 (295–345)
aexcept for number of patients, b95 % CI, cdifference is significant between first 6 months and the period measured, 95 % CI
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services through clinics in certain high prevalence settings
such as prisons or cities may be preferable [53, 54],
although this strategy requires further study.
Regarding our third research question about patients’
financial burden, the study shows that patient costs per
visit are US$10 and US$11, for patients with CD4 cell
counts below and above 200 cells/mm3. This relates to
approximately 14 and 7 % of their monthly expenditure
(a proxy of monthly income), respectively. Especially for
patients with CD4 cell counts <200 cells/mm3 these
costs could be a barrier, as it exceeds 10 % of their
monthly expenditure and can be considered to be cata-
strophic for a household economy [55].
Transportation comprises the highest proportion of
costs: 62 and 43 % for patients with CD4 cell counts below
and above 200 cells/mm3, respectively, and this is compar-
able with the finding of Riyarto et al. [16] in Indonesia. A
study by Haroen et al. [49] in Bandung, Indonesia, and
international studies by Portelli et al. [47], Brinkhof et al.
[48], and Posse et al. [15] have shown that transportation
costs are a common reason why patients cease ARV. This
information provides another reason to scale up ART at
community level, as it likely reduces transportation costs
for patients and may increase the uptake of ART, espe-
cially of patients with CD4 cell counts <200 cells/mm3.
Study limitations
Our results should be interpreted with some caution. First,
this study has evaluated a contextualized ART service deliv-
ery model, which may hamper the generalizability of its
results. Cost structures and levels as well as patient popula-
tions are likely to vary between clinics, and specific costing
studies for other settings (e.g., other hospitals, community/
primary health centers, and prisons) should be considered.
Caution should be exercised when interpreting our result
in other resource limited settings. Second, we may have
overestimated the total patient costs of seeking and under-
going care as this was based on assumptions regard-
ing patients’ labour productivity losses, and not on
empirical data collection on these losses per se. Third,
although we have conducted a time motion study to
control for inefficiency in personnel performance and
equipment use related to ART delivery in the clinic,
discrepancies may still exist, and we may have over-
or undervalued the total costs. Fourth, we did not
perform any comparison between WHO CHOICE es-
timates (that we used for calculating inpatient cost)
and any local data. Although this is an important as-
pect, currently there is very limited local data avail-
able to do this comparison. Fifth, it is important to
note that the unit costs and prices data that we used
are from year 2010–2012, depending on availability.
As such, we believe these unit costs have changed
overtime and our results should be interpreted with
this note in mind (e.g. ARV drugs prices may have
decreased since government are producing more ARV
locally [2], patients monthly expenditure has been ris-
ing due to inflation).
Conclusion
Three main conclusions can be derived from our study.
First, we show that the costs of providing ART are highest
during the early phase of treatment, and will decrease and
stabilize as treatment progresses. Second, our findings sug-
gest that costs reduction can be potentially realized by early
treatment initiation (which may reduce hospitalization, OI
drug/treatment costs, and patient mortality) and by apply-
ing alternative laboratory tests with caution. Third, scaling
up ART at the community level in certain high prevalence
settings has potential to save costs and improve uptake and
adherence. However, provision of ART at all community
clinics seems inefficient due to the low prevalence in the
general population and options to select certain clinics in
high prevalence areas need further investigation.
Table 5 Recommendation on role of clinics in delivering ARTa
Costs Items Type of Clinic
Hospital Community/Primary Health Care Centre
Hospitalization + -
Outpatient visits +/- +
OI treatment +b +
ARV drugs +/- +
CD4 test + -
Viral load test +c -
Routine lab test + +/-
ART antiretroviral treatment
a‘ + ’ and ‘-’ denote respectively a role of high and low importance for the
clinic in the specified activities in HIV/AIDS control
bfor severe cases, c if necessary
Table 4 Patient costs of accessing ART (patient’s perspective) (US$)
CD4 level at the
start of ART
Estimated average per visit access costs Monthly
household
expenditure
Average transportation cost Average estimated
productivity loss
Average fee for clinic Average per visit total costs
0 – 200 (n = 17)a,b 5.9 (0–12.2) 1.1 (0.5–1.7) 2.4 (2.0–2.7) 9.6 (2.9 – 16.3) 71.4 (41.9 – 101.0)
>200 (n = 23)a,b 4.7 (2.4–7.1) 3.2 (1.8–4.6) 2.2 11.0 (3.7 – 18.3) 147 (72 – 221)
aaverage, b95 % CI
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Appendix
Table 6 Yearly Cost of ART outpatient service (US$)
Type of Cost US$ (2010) Percent
1. CAPITAL COST (Annualized)
1.1 Personnel (trainings & workshops) 111.37 0.5
1.2 Building/Space 477.24 2.0
1.3 Equipments 510.72 2.1
Subtotal 1099.33
2. RECURRENT COST
2.1 Personnel (number) 21123.40 91.7
Medical doctor (4) 6701.66
Nurse (2) 5370.67
Laboratory (1) 1196.22
Administration and cleaning service (6) 15178.81
2.2 Supplies 895.13 3.7
Subtotal 23018.54
T o t a l 24117.86
Unit cost per visit 11.69
Table 7 Average unit costs of OI treatment by CD4 cell count at the beginning of ART (US$)
CD4 cell
count
Period
Before ARTa 1–6 monthsa 7–12 monthsa 13–18 monthsa 19–24 monthsa
0–50 1 (0–2) 113 (48–179) 23 (3–42) 7 (0–16) 25 (0–60)
50–100 0.4 (0–1) 22 (1–43) 64 (0–170) 0.4 (0–1) 0.3 (0–1)
100–150 - 37 (0–94) 3 (0.1–7) 2 (0–3) 0.2 (0–0.4)
150–200 - 4 (0–9) 0.2 (0–1) 0.4 (0–1) -
>200 - 0.1 (0–0.3) - - -
a95 % CI
Table 8 Unit Costs per Cost Item (US$)
Costs Item Unit Cost Source
Inpatient day 19.2 WHO CHOICE
Outpatient visit 11.7 Own calculation
Monthly average unit costs of ARV drugs (min-max)
First line 28 (7–79) Kimia Farma
Second line 90 (56–117) Kimia Farma and Bender et al., [20]
CD4 test 13.2 Hospital Decree
Viral load test 66 Hospital Decree
Average unit costs of laboratory tests (confidence interval) 6 (4–8) Hospital Decree
Table 9 Mean one way t-test result (P-value), 95 % CI
Mean t-test for unit cost per 2 years per patient between CD4 cell count
group
Lowest CD4 cell count group CD4 cell count
51–100 101–150 151–200 >200
0–50 0.49 0.03 0.004 0.0006
Mean t-test for unit cost per 6 months per patient between period by
CD4 cell count group
CD4 cell count in 0–6 months Period (months)
7–12 13–18 19–24
0–50 0.008 0.006 0.007
51–100 0.20 0.30 0.03
101–150 0.40 0.36 0.19
151–200 0.42 0.47 0.17
>200 0.47 0.49 0.01
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